Davis Gregory D 4

What Happened

• Gregory D. Davis, Head of Research & Technology at Sangamo Therapeutics (SGMO), had 7,721 shares withheld on January 22, 2026 to satisfy mandatory tax withholding related to vested restricted stock units (RSUs). The shares were valued using the issuer's closing price of $0.3985 per share, resulting in proceeds of approximately $3,077. This was a tax-withholding disposition to the company (reporting code F), not an open-market sale.

Key Details

• Transaction date and price: January 22, 2026; $0.3985 per share (issuer closing price).
• Shares surrendered: 7,721; reported value ≈ $3,077.
• Shares owned after transaction: the filing does not state a single total explicitly; it notes vested and outstanding RSU components (see footnotes below).
• Notable footnotes:
  • F1: Shares were surrendered solely for mandatory tax withholding and this disposition is to the issuer for reporting purposes, not a discretionary market sale.
  • F2: Breakdown of RSU holdings referenced in the filing: 11,029 shares from a Jan 22, 2024 RSU vesting installment, 2,022 shares from a Feb 24, 2023 RSU grant (vesting through Feb 24, 2026), and 49,726 shares from a Feb 25, 2025 RSU grant (with future vesting schedule).
  • F3: Includes 5,000 shares acquired under the 2020 Employee Stock Purchase Plan.
  • F4: Reporting person previously transferred 8 shares to an ex-spouse (no longer beneficially owned).
• Timeliness: Transaction occurred Jan 22, 2026; Form 4 filed Jan 26, 2026 (within the standard two-business-day reporting window).

Context

• This was a routine tax-withholding event tied to RSU vesting (a common administrative transaction). It does not represent a discretionary sale or purchase and should not be interpreted alone as a signal of insider sentiment.